These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36747360)

  • 1. Immunogenicity of SARS-CoV-2 Vaccine in Kidney Transplant Recipients: A Cross-Sectional Study in Korea.
    Song SH; Chung KY; Jee Y; Chung HS; Kim K; Minn D; Kim SK
    J Korean Med Sci; 2023 Feb; 38(5):e22. PubMed ID: 36747360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.
    Charmetant X; Espi M; Benotmane I; Barateau V; Heibel F; Buron F; Gautier-Vargas G; Delafosse M; Perrin P; Koenig A; Cognard N; Levi C; Gallais F; Manière L; Rossolillo P; Soulier E; Pierre F; Ovize A; Morelon E; Defrance T; Fafi-Kremer S; Caillard S; Thaunat O
    Sci Transl Med; 2022 Mar; 14(636):eabl6141. PubMed ID: 35103481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
    Benning L; Morath C; Bartenschlager M; Kim H; Reineke M; Beimler J; Buylaert M; Nusshag C; Kälble F; Reichel P; Töllner M; Schaier M; Klein K; Benes V; Rausch T; Rieger S; Stich M; Tönshoff B; Weidner N; Schnitzler P; Zeier M; Süsal C; Hien Tran T; Bartenschlager R; Speer C
    Am J Transplant; 2022 Jul; 22(7):1873-1883. PubMed ID: 35384272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
    J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Mittal A; Solera JT; Ferreira VH; Kothari S; Kimura M; Pasic I; Mattsson JI; Humar A; Kulasingam V; Ierullo M; Kumar D; Hosseini-Moghaddam SM
    Transplant Cell Ther; 2023 Nov; 29(11):706.e1-706.e7. PubMed ID: 37582470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
    Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
    JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of two doses of SARS-CoV-2 mRNA vaccine in kidney transplant recipients with low-dose rituximab.
    Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N
    Int J Urol; 2022 Nov; 29(11):1279-1286. PubMed ID: 35863901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients.
    Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N
    Front Immunol; 2022; 13():1050211. PubMed ID: 36532067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study).
    Bruminhent J; Setthaudom C; Chaumdee P; Boongird S; Kiertiburanakul S; Malathum K; Nongnuch A; Phuphuakrat A; Jirasiritham S; Janphram C; Thotsiri S; Upama S; Assanatham M;
    Am J Transplant; 2022 Mar; 22(3):813-822. PubMed ID: 34657386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
    Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
    J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Low Anti-spike Antibody Levels After the Third Dose of SARS-CoV-2 Vaccination and Hospitalization due to Symptomatic Breakthrough Infection in Kidney Transplant Recipients.
    Han A; Min S; Jo EA; Lee H; Kim YC; Han SS; Kang HG; Ahn YH; Oh I; Song EY; Ha J
    Ann Lab Med; 2024 Jan; 44(1):64-73. PubMed ID: 37665287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detectable plasma severe acute respiratory syndrome coronavirus 2 spike antigen is associated with poor antibody response following third messenger RNA vaccination in kidney transplant recipients.
    Karaba AH; Swank Z; Hussain S; Chahoud M; Durand CM; Segev DL; Robien MA; Heeger PS; Larsen CP; Tobian AAR; Walt DR; Werbel WA
    Transpl Infect Dis; 2024 Jun; 26(3):e14281. PubMed ID: 38618895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.
    Kimura M; Ferreira VH; Kothari S; Pasic I; Mattsson JI; Kulasingam V; Humar A; Mah A; Delisle JS; Ierullo M; Majchrzak-Kita B; Kumar D; Hosseini-Moghaddam SM
    Transplant Cell Ther; 2022 Oct; 28(10):706.e1-706.e10. PubMed ID: 35914727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients.
    Kemlin D; Gemander N; Depickère S; Olislagers V; Georges D; Waegemans A; Pannus P; Lemy A; Goossens ME; Desombere I; Michiels J; Vandevenne M; Heyndrickx L; Ariën KK; Matagne A; Ackerman ME; Le Moine A; Marchant A
    Am J Transplant; 2023 May; 23(5):649-658. PubMed ID: 36773936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.
    Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients.
    Eren Sadioğlu R; Demir E; Evren E; Aktar M; Şafak S; Artan AS; Meşe S; Ağaçfidan A; Çınar G; Önel M; Karahan ZC; Şengül Ş; Keven K; Türkmen A
    Transpl Infect Dis; 2021 Dec; 23(6):e13740. PubMed ID: 34606134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
    Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R
    Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
    Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
    Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.
    Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F
    J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.